Previous 10 | Next 10 |
home / stock / rhhbf / rhhbf news
2023-10-29 12:00:27 ET More on PBMs Cigna PBM unit Express Scripts sued for overcharging pharmacies FTC investigating purchasing organizations that work on behalf of PBMs Eli Lilly, Novo, Sanofi and leading PBMs accused in California over insulin prices CVS H...
2023-10-26 09:00:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. A historically wide di...
2023-10-26 08:45:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. A historically wide di...
2023-10-24 09:25:49 ET Summary Roche Holding AG acquires Telavant Holdings for $7.1B upfront and $150M milestone payment, potentially very interesting deal. Roivant Sciences owns a 75% equity interest in Telavant Holdings. Curiously, Roivant Sciences stock sold off on the news...
2023-10-23 06:42:07 ET Summary Roivant Sciences announces $7.1B deal with Roche to acquire Telavant and its new bowel disease therapy. Stonepeak to acquire Textainer Group for $2.1B. Japan's competition watchdog to investigate Google over antimonopoly practices related to its ...
2023-10-23 03:10:38 ET More on Roche, Roivant Sciences Skin In The Game: Behind Roivant's Significant Rise Be Patient, Roche Is A Clear Buy At This Price Roche: Positive Readouts From Pipeline Roche: 2023 Should Mark The Bottom Roche slips after in-li...
2023-10-20 09:38:08 ET Summary Solid balance sheet, higher DPS expected, and firepower. Roche is a company to have. COVID-19 has positively impacted the company, and now Wall Street is discounting lower sales estimates. However, Roche is growing nicely. Despite a challenging e...
2023-10-19 19:15:23 ET Summary Positive interim analysis from its phase 2 CALLIPER study achieved, showing a statistically significant reduction in neurofilament light chain (NfL) in progressive multiple sclerosis patients when given vidofludimus calcium. Vidofludimus calcium perf...
2023-10-19 12:10:28 ET More on BioNTech BioNTech: This Beaten Pandemic Star Will Capitalize On Oncology Treatments BioNTech: Renewed COVID Focus Might Spark Potential Share Price Boost BioNTech: Not Just Another Jab In The Arm Biggest stock movers today: Vist...
2023-10-19 08:31:42 ET More on PTC, Roche, etc. Recursion Pharmaceuticals: Wet Lab Meets Silicon, A Tale Of Two Bottom Lines Roche: Positive Readouts From Pipeline Roche: 2023 Should Mark The Bottom Roche slips after in-line Q3 sales Roche in pact wit...
News, Short Squeeze, Breakout and More Instantly...
Economist Impact report, Advancing the frontier of health and technology integration: The 2023 Digital Health Barometer highlights opportunities in digitalisation of healthcare Canada NewsWire The report shows digital health technologies demonstrate value, yet integrating th...
Development in Alzheimer's disease diagnosis in Canada: New tests help patients and caregivers make timely decisions Canada NewsWire Roche's Cerebrospinal Fluid (CSF) assays address unmet needs in the detection of amyloid pathology by offering greater accessibility and support...